{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Comparator+Condition&page=12", "query": { "intervention": "Comparator Condition", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 892, "total_pages": 90, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Comparator+Condition&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Comparator+Condition&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T06:56:54.051Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06164951", "title": "A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Achondroplasia" ], "interventions": [ { "name": "Infigratinib 0.25 mg/kg/day", "type": "DRUG" }, { "name": "Placebo Comparator 0.25 mg/kg/day", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QED Therapeutics, a BridgeBio company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "3 Years to 17 Years" }, "enrollment_count": 114, "start_date": "2023-11-10", "completion_date": "2025-12-18", "has_results": false, "last_update_posted_date": "2026-03-17", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 7, "location_summary": "San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06164951" }, { "nct_id": "NCT01230853", "title": "A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "Active Comparator: A", "type": "DRUG" }, { "name": "Placebo Comparator B", "type": "DRUG" }, { "name": "Active Comparator B", "type": "DRUG" }, { "name": "Placebo Comparator A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 80, "start_date": "2010-08", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2020-11-23", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 8, "location_summary": "Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01230853" }, { "nct_id": "NCT00158600", "title": "A Placebo-Controlled Study of Safety and Effectiveness of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pompe Disease (Late-onset)", "Glycogen Storage Disease Type II (GSD-II)", "Acid Maltase Deficiency Disease", "Glycogenosis 2" ], "interventions": [ { "name": "alglucosidase alfa", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": null, "sex": "ALL", "summary": "8 Years and older" }, "enrollment_count": 90, "start_date": "2005-09", "completion_date": "2007-09", "has_results": true, "last_update_posted_date": "2015-04-28", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 5, "location_summary": "Beverly Hills, California • Washington D.C., District of Columbia • St Louis, Missouri + 2 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00158600" }, { "nct_id": "NCT03661398", "title": "Caisson Transcatheter Mitral Valve Replacement (TMVR)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Mitral Regurgitation", "Mitral Valve Disease", "Mitral Valve Failure", "Mitral Disease", "Valve Heart Disease", "Valve Disease, Heart" ], "interventions": [ { "name": "Transcatheter Mitral Valve Replacement", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Caisson Interventional LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2017-07-20", "completion_date": "2025-08", "has_results": false, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03661398" }, { "nct_id": "NCT05055128", "title": "A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Erosive Esophagitis" ], "interventions": [ { "name": "X842", "type": "DRUG" }, { "name": "X842 Dummy", "type": "DRUG" }, { "name": "Lansoprazole", "type": "DRUG" }, { "name": "Lansoprazole Dummy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cinclus Pharma Holding AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 248, "start_date": "2021-08-11", "completion_date": "2022-09-01", "has_results": true, "last_update_posted_date": "2026-07-01", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05055128" }, { "nct_id": "NCT00557921", "title": "Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Coronary Syndrome", "Myocardial Infarction", "Coronary Artery Disease", "Percutaneous Coronary Intervention" ], "interventions": [ { "name": "CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin", "type": "DRUG" }, { "name": "Plavix (clopidogrel 75 mg) and aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogentus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 5000, "start_date": "2007-12", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2009-01-28", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 247, "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Geneva", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00557921" }, { "nct_id": "NCT00864344", "title": "A Relative Bioavailability Study of Sertraline HCl 100 mg Tablets Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Sertraline HCl 100 mg tablets, single dose", "type": "DRUG" }, { "name": "Zoloft® 100 mg tablets, single dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2004-08", "completion_date": "2004-08", "has_results": false, "last_update_posted_date": "2010-08-16", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00864344" }, { "nct_id": "NCT02553733", "title": "Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "Beetroot juice", "type": "DRUG" }, { "name": "Beetroot juice placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "David N. Proctor, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "21 Years to 85 Years" }, "enrollment_count": 11, "start_date": "2015-12", "completion_date": "2020-02", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02553733" }, { "nct_id": "NCT02939976", "title": "Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Myocardial Infarction" ], "interventions": [ { "name": "Single Vessel Disease", "type": "DEVICE" }, { "name": "Multi-vessel Disease, Culprit Vessel Only", "type": "PROCEDURE" }, { "name": "Multi-vessel Disease, Complete Revascularization", "type": "PROCEDURE" }, { "name": "Medtronic Resolute family of stents", "type": "DEVICE" }, { "name": "Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology", "type": "DEVICE" }, { "name": "Terumo Glidesheath Slender", "type": "DEVICE" }, { "name": "Terumo TR Band Radial Compression Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE", "PROCEDURE" ], "sponsor": "David Kong, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 427, "start_date": "2017-08-30", "completion_date": "2023-07-19", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02939976" }, { "nct_id": "NCT07658391", "title": "Optimizing CBSST With Executive Function Training for Schizophrenia (R33)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizophrenia", "Schizoaffective Disorder" ], "interventions": [ { "name": "E-CBSST", "type": "BEHAVIORAL" }, { "name": "E-SC", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 106, "start_date": "2026-10-01", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-25T06:56:54.051Z", "location_count": 2, "location_summary": "San Diego, California • Dallas, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07658391" } ] }